These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6454138)

  • 1. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages.
    Kipnis TL; David JR; Alper CA; Sher A; da Silva WD
    Proc Natl Acad Sci U S A; 1981 Jan; 78(1):602-5. PubMed ID: 6454138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
    Sher A; Hieny S; Joiner K
    J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody.
    Schenkman S; Güther ML; Yoshida N
    J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
    Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
    Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B.
    Joiner K; Sher A; Gaither T; Hammer C
    Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6593-7. PubMed ID: 2944112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement.
    Tomlinson S; Pontes de Carvalho LC; Vandekerckhove F; Nussenzweig V
    J Immunol; 1994 Oct; 153(7):3141-7. PubMed ID: 8089492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lytic rabbit IgG for tissue culture trypomastigotes of Trypanosoma cruzi alters the extent and form of complement deposition.
    Rimoldi MT; Tartanian A; Joiner KA
    Exp Parasitol; 1989 Feb; 68(2):160-7. PubMed ID: 2647504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components.
    Iida K; Whitlow MB; Nussenzweig V
    J Exp Med; 1989 Mar; 169(3):881-91. PubMed ID: 2494292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.
    Krettli AU; Pontes de Carvalho LC
    Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
    Lambré CR; Kazatchkine MD; Maillet F; Thibon M
    J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host and parasite factors affecting the invasion of mononuclear phagocytes by Trypanosoma cruzi.
    Nogueira N
    Ciba Found Symp; 1983; 99():52-73. PubMed ID: 6196166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Externally disposed membrane polypeptides of intact and protease-treated Trypanosoma lewisi correlated with sensitivity to alternate complement pathway-mediated lysis.
    Sturtevant JE; Balber AE
    Infect Immun; 1983 Dec; 42(3):869-75. PubMed ID: 6358042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trypanosoma cruzi: differences in cell surface interaction of circulating (trypomastigote) and culture (epimastigote) forms with macrophages.
    Zenian A; Kierszenbaum F
    J Parasitol; 1983 Aug; 69(4):660-5. PubMed ID: 6355428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of carbohydrates, periodate and enzymes in the process of endocytosis of Trypanosoma cruzi by macrophages.
    de Araújo Jorge TC; de Souza W
    Acta Trop; 1984 Mar; 41(1):17-28. PubMed ID: 6143479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.
    Norris KA
    Infect Immun; 1998 Jun; 66(6):2460-5. PubMed ID: 9596703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evasion of Trypanosoma cruzi from complement lysis.
    Kipnis TL; da Silva WD
    Braz J Med Biol Res; 1989; 22(1):1-16. PubMed ID: 2667667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis.
    Krettli AU; Weisz-Carrington P; Nussenzweig RS
    Clin Exp Immunol; 1979 Sep; 37(3):416-23. PubMed ID: 116784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.